Vaxcyte marked a -7.3% change today, compared to -0.0% for the S&P 500. Is it a good value at today's price of $59.66? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases.
-
Vaxcyte belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 30.21 and an average price to book (P/B) of 4.08
-
The company's P/B ratio is 4.04
-
Vaxcyte has a trailing 12 month Price to Earnings (P/E) ratio of -12.6 based on its trailing 12 month price to earnings (EPS) of $-4.73 per share
-
Its forward P/E ratio is -13.9, based on its forward earnings per share (EPS) of $-4.3
-
PCVX has a Price to Earnings Growth (PEG) ratio of 0.58, which shows the company is very undervalued compared to its earnings growth estimates.
-
Over the last four years, Vaxcyte has averaged free cash flows of $-107488500.0, which on average grew -54.7%
-
Vaxcyte has moved 37.9% over the last year compared to 20.4% for the S&P 500 -- a difference of 17.5%
-
PCVX has an average analyst rating of buy and is -15.77% away from its mean target price of $70.83 per share